儿童急性淋巴细胞白血病复发率及复发后结局的三十年间时间趋势:一项北欧人群队列研究
该研究比较了1992至2018年北欧三个连续儿童血液肿瘤学会试验中Ph阴性急性淋巴细胞白血病患儿的复发率、预后因素及复发后生存。5年累积复发率在ALL1992和ALL2000试验中分别为17.3%和16.5%,在ALL2008试验中降至8.4%;复发后4年总生存率为56.6%,未见统计学显著的时间改善。年龄≥10岁、T细胞免疫表型、骨髓受累、早期和极早期复发、低二倍体及唐氏综合征均独立预测复发后更差结局。
要点
- ALL2008试验的5年累积复发率降至8.4%,低于ALL1992的17.3%和ALL2000的16.5%。
- 复发后4年总生存率为56.6%(95% CI 52.5-60.5%),未见统计学显著的时间改善。
- 年龄≥10岁、T细胞免疫表型、骨髓受累、早期和极早期复发、低二倍体及唐氏综合征独立预测复发后更差结局。
核心结论
- 儿童ALL原发治疗的改善减少了复发,但剩余复发的结局未能改善,提示复发选择偏倚并向更难治愈的复发倾斜,呼吁新的治疗策略。
研究设计与样本
- 北欧人群队列研究,比较三个连续北欧儿童血液肿瘤学会(NOPHO)试验中1992至2018年诊断的Ph阴性ALL患儿。
- 共纳入4458例1.0-14.9岁患儿,其中638例以复发为主要事件。
主要发现
- 5年累积复发率:ALL1992试验为17.3%(95% CI 15.4-19.2%),ALL2000试验为16.5%(95% CI 14.3-18.8%),ALL2008试验降至8.4%(95% CI 7.0-10.1%)。
- 首次完全缓解持续时间和复发部位随时间未见变化;ALL2008试验中高二倍体亚型和t(12;21)减少。
- 复发后4年总生存率为56.6%(95% CI 52.5-60.5%),未观察到统计学显著的时间改善。
- 年龄≥10岁、T细胞免疫表型、骨髓受累、早期和极早期复发、低二倍体及唐氏综合征均独立预测复发后更差结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapse remains the main obstacle to curing childhood acute lymphoblastic leukemia (ALL). The aims of this study were to compare incidence of relapse, prognostic factors, and survival after relapse between three consecutive Nordic Society of Pediatric Hematology and Oncology trials. Relapse occurred as a primary event in 638 of 4 458 children (1.0-14.9 years) diagnosed with Ph-negative ALL between 1992 and 2018. The 5-year cumulative incidence of relapse was 17.3% (95% CI 15.4-19.2%) and 16.5% (95% CI 14.3-18.8%) for patients in the ALL1992 and ALL2000 trials, respectively, but decreased to 8.4% (95% CI 7.0-10.1%) for patients in the ALL2008 trial. No changes in duration of first complete remission and site of relapse were observed over time; however, high hyperdiploidy, and t(12;21) decreased in the ALL2008 trial. The 4-year overall survival after relapse was 56.6% (95% CI 52.5-60.5%) and no statistically significant temporal improvements were observed. Age ≥10 years, T-cell immunophenotype, bone-marrow involvement, early and very early relapse, hypodiploidy, and Down syndrome all independently predicted worse outcome after relapse. Improvements in the primary treatment of childhood ALL has resulted in fewer relapses. However, failure to improve outcome of remaining relapses suggests a selection of harder-to-cure relapses and calls for new therapeutic strategies.
引用
- Jensen KS, Oskarsson T, Lähteenmäki PM, et al. Temporal changes in incidence of relapse and outcome after relapse of childhood acute lymphoblastic leukemia over three decades; a Nordic population-based cohort study. Leukemia. 2022. PMID: 35314777. doi:10.1038/s41375-022-01540-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。